Pioglitazone improved retinopathy in mice models through decreasing inflammation and neovascularisation in the retina in diabetic mice by decreasing TNF-alpha through stimulation of adiponectin, a known natural anti-inflammatory mediator [45]. The gene discussed is TNF; the disease is retinal disorder.